ImCheck Therapeutics

🚀 Exciting News! ImCheck is thrilled to announce the appointment of Dr. Stephan Braun as our new Chief Medical Officer. Dr. Braun joins us to drive the clinical development of our lead candidate, ICT01, a groundbreaking γ9δ2 T cell-activating monoclonal antibody targeting BTN3A, as it advances toward later-stage clinical trials in multiple cancer indications. He will also oversee our expanding pipeline of immunotherapeutic antibodies designed to harness both innate and adaptive immune responses. With over 30 years of drug development experience from a distinguished career in the pharmaceutical industry and academic research, Dr. Braun is a tremendous addition to our team. Welcome aboard, Stephan! 🌟 #Leadership #ClinicalTrials #ICT01

🚀 Exciting News from ImCheck at #ASCO2024! 🚀 We are thrilled to share the interim data from our Phase I/II EVICTION study, which demonstrate a favorable safety profile and promising efficacy for ICT01 in combination with pembrolizumab in refractory melanoma patients. ImCheck intends to further investigate this combination regimen in refractory solid tumors, where patients have limited treatment options. Do not miss the poster session presented by Dr. Stéphane Champiat, Gustave Roussy. 📅 Saturday, June 1st, 2024 🕐 1:30–4:30 PM CST 📌 Session title: Melanoma/Skin Cancers 🔢 Abstract number: 9534 📍 Poster board: 318 #ICT01 #Pembrolizumab #ASCOAnnualMeeting #ClinicalTrials #Oncology #Melanoma See our press release : https://lnkd.in/gP-fVFpm

ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation   🏆 ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech 2030 program announced nearly a year ago. 👩⚕️ ImCheck is one of the few therapeutics-focused biotech and healthcare start-up/scale-up companies selected as one of the 120 companies for the fifth edition of the French Tech Next40/120 program and as one of the 125 recipients of the first edition of the French Tech 2030 program. 💪 The awards highlight ImCheck as one of the leaders among the companies supporting the ambitions of the Innovation Santé 2030 plan.   ImCheck Therapeutics announced today that it is part of the prestigious French Tech 120 for the fifth year in a row. Being once again a #FT120 winner and one of the 125 companies selected for the #FrenchTech2030 underscores ImCheck's potential to become a world-class leader in immunotherapy. ImCheck benefits from these two programs of excellence launched by the French government, serving one of the 6 priorities of France 2030: positioning France as a sovereign European leader in healthcare innovation.   "Anchored in our regional healthcare ecosystem in Marseille and backed by a syndicate of prestigious international investors, we are delighted to once again have the support and recognition of the French government and its agencies, and intend to actively contribute to France's sovereignty in healthcare innovation. We are more determined than ever to become a champion in immunotherapy on a global scale," said Pierre d'Epenoux, CEO of ImCheck Therapeutics.   We would like to thank Clara Chappaz Lise ALTER Marina Ferrari Bruno Le Maire Gabriel Attal and Emmanuel Macron for their support. #France2030 #FT120 #FrenchTech #FrenchTech2030 #HealthInnovationAgency #Innovation #Cancer

Today, on International Women's Day, ImCheck Therapeutics proudly stands with women everywhere, celebrating the remarkable resilience of the women who drive innovation and progress within our organization. To the women on our team. Your talent, dedication and fearlessness are the driving force behind our success. We applaud your courage and commitment to excellence. To our women leaders. Thank you for paving the way and inspiring the next generation of talent with grace. Your vision and determination are invaluable assets to our company. On this special day, let's continue to champion equality and diversity in the workplace and recognize the collective strength that propels us forward. Together, we can create a more inclusive and empowering environment for all!

Ravi de proposer ma candidature au Conseil d'Administration de La French Tech Aix-Marseille Région Sud, au sein du Collège #Startups! Je serai très heureux de partager mon expérience, notamment chez ImCheck Therapeutics, avec les dirigeants des startups du territoire, pour les aider à maitriser les codes des levées de fonds et de la gouvernance. J'entends également contribuer plus largement à attirer les financements pour soutenir le démarrage et le développement durable de nos entreprises.

In celebration of the 9th International Day of Women and Girls in Science, we salute and celebrate an oustanding team of women who have acted and continue to act as agents of change to accelerate innovation, development and change in our organization. Your contributions have shaped this company and we commend your courage, talent and fearlessness. To our leaders, we salute you for charting the course, for being trailblazers and for showing our junior employees that they too can pursue their dreams. From all of us at ImCheck... Thank You !

We are delighted to be one of the "19 French biotechs to know" in Labiotech.eu. Thank you Jules ADAM for this nice focus on the French innovation ecosystem, notably in oncology, and for your accurate understanding of what we do at ImCheck Therapeutics!

Accédez ici au replay du webinaire BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle du 5 décembre dernier. Notre CEO Pierre d'Epenoux et Marina Iché, CEO d’ILIFE CONSULTING, partenaire de longue date de notre développement clinique, y racontent plus de 5 ans de collaboration fructueuse au service du succès d'ImCheck !

ILIFE CONSULTING nous accompagne depuis 2017 dans notre stratégie et notre développement clinique. Nous vous invitons à vous joindre au webinaire BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle du 5 décembre où notre CEO Pierre d'Epenoux sera mis à l’honneur au côté de Marina Iché, CEO d’ILife consulting pour plonger dans le sujet : « ILife Consulting & ImCheck : le développement clinique, pilier du succès ! » 👉 Inscrivez-vous ici pour participer au webinaire https://lnkd.in/e3URJCSQ

#SITC23 Poster Presentation Today! Join us today from 12:00-1:30 pm and 5:10-6:40 pm PT for our poster presentation on the EVICTION-2 study. Clinical Trials in Progress Session, Abstract #715 Discover the interim data from the EVICTION-2 study confirming a safety and tolerability profile and a broad anti-tumor immune response that is durable over multiple treatment cycles. “The effect of ICT01 with low dose IL-2 on anti-tumor immunity suggests the combination regimen holds promise, notably for the treatment of patients with low circulating γ9δ2 T cells and, together with the results from the EVICTION study, underlines the strong immunotherapeutic potential of ICT01 in oncology,” commented Pierre d'Epenoux, Chief Executive Officer of ImCheck Therapeutics. Read the press release: https://lnkd.in/eyMd8-Hb #ImCheckTherapeutics #SITC23 #ICT01 #SolidTumors #ClinicalTrials #EVICTION2